Shandong Sinobioway Biomedicine 대차 대조표 상태

재무 상태 기준 확인 6/6

Shandong Sinobioway Biomedicine 의 총 주주 지분은 CN¥2.2B 이고 총 부채는 CN¥0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 CN¥2.3B 및 CN¥90.9M 입니다.

주요 정보

부채 비율

CN¥0

부채

이자 보상 비율	n/a
현금	CN¥428.85m
주식	CN¥2.20b
총 부채	CN¥90.89m
총 자산	CN¥2.30b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Oct 08

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Aug 19

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Mar 06

재무 상태 분석

단기부채: 002581 의 단기 자산 ( CN¥721.9M )이 단기 부채( CN¥64.6M ).

장기 부채: 002581 의 단기 자산( CN¥721.9M )이 장기 부채( CN¥26.3M ).

부채 대 자본 내역 및 분석

부채 수준: 002581 부채가 없습니다.

부채 감소: 002581 는) 부채 대 자기자본 비율이 28.6% 였던 5년 전과 비교하여 부채가 없습니다.

부채 범위: 002581 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 002581 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Shandong Sinobioway Biomedicine 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.067 (vs CN¥0.13 in 3Q 2023)

There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.003 loss per share (vs CN¥0.049 loss in 2Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

First quarter 2024 earnings released: CN¥0.042 loss per share (vs CN¥0.033 loss in 1Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, May 22, 2024

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Shandong Sinobioway Biomedicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.061 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.033 profit in 2Q 2022)

Full year 2022 earnings released: CN¥0.022 loss per share (vs CN¥0.41 profit in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.061 (vs CN¥0.32 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.17 in 2Q 2021)

Shandong Sinobioway Biomedicine Co., Ltd. Announces Executive Appointments

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, Aug 22, 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.037 in 1Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.021 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.045 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.29 loss per share (vs CN¥0.096 profit in FY 2019)

New 90-day low: CN¥9.90

New 90-day low: CN¥12.64

New 90-day low: CN¥15.21

New 90-day low: CN¥17.15

Third quarter earnings released

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan

New 90-day low: CN¥17.55

First half earnings released

New 90-day low - CN¥19.50

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기